Daily closing price · 250 sessions
Quantitative price outlook based on available market signals. Not financial advice.
Indicators calculated from the stored daily price history.
A verified, data-driven analysis will be generated here from price action, technical indicators, fundamentals, earnings and market context.
Dedicated research sections for 2026, 2030, 2035, 2040 and 2050. Numerical targets will appear only after the long-horizon model is validated.
Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2026 research →Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2030 research →Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2035 research →Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2040 research →Research inputs: earnings, revenue growth, valuation, technical regime, volatility, sector context and market conditions.
Read 2050 research →Historical outcomes are shown only after a prediction has matured and been evaluated.
Absolute percentage error: 4.46%
Absolute percentage error: 6.36%
Only stories explicitly associated with this stock are shown.
Eli Lilly's GLP-1 franchise, led by Mounjaro and Zepbound, generated $27.7 billion in first-half 2026 sales and continues driving growth. The company's oral obesity pill Foundayo shows encouraging uptake with coverage across major PBMs, while newer therapies grew 121% in Q2, diversifying revenue beyond GLP-1. However, the stock trades at a premium 26.3x forward earnings amid intensifying competition from Novo Nordisk and smaller biotechs in the oral GLP-1 market. Analysts recommend existing investors hold while new investors consider accumulating on market corrections.
The global autoimmune disease therapeutics market is projected to grow from USD 132.75 billion in 2025 to USD 254.60 billion by 2034, at a CAGR of 7.5%. Growth is driven by rising autoimmune disease diagnoses, increased adoption of biologics and targeted oral therapies, biosimilar expansion, and emerging cell and gene therapies. Biologics dominate with 66% market share, TNF inhibitors lead drug classes at 29%, and rheumatoid arthritis accounts for 34% of revenue. North America holds 44% regional share while Asia-Pacific is expected to grow fastest.
Eli Lilly dominates the weight loss drug market with 60% U.S. share and is gaining ground in the new oral GLP-1 pill segment. While Novo Nordisk's Wegovy pill currently leads in prescriptions (183,000 vs. 47,500 for Lilly's Foundayo), the gap is narrowing—mirroring Lilly's previous dominance shift in injectable GLP-1 drugs. Lilly's Foundayo offers convenience advantages, and analysts project the weight loss drug market to reach $100 billion by decade's end.
The global immunotherapy drugs market is experiencing significant growth driven by advances in biotechnology, rising demand for targeted treatments, and expanding therapeutic applications across cancer, autoimmune, and inflammatory diseases. Key growth factors include increasing disease burden, robust drug pipelines, personalized medicine adoption, and combination therapy development. The Americas and Europe remain dominant markets, while Asia-Pacific is emerging as a high-growth region. Major pharmaceutical and biotech companies are increasing R&D investments and collaboration to accelerate innovation.
The iShares U.S. Pharmaceuticals ETF (IHE) is a passively managed fund offering broad exposure to the Healthcare-Pharma sector with $1.63 billion in assets. The ETF has delivered strong year-to-date returns of 20.69% and 45.67% over the past year, though it carries higher risk with a beta of 0.49 and standard deviation of 16.8%. It holds approximately 60 pharmaceutical companies with top holdings including Johnson & Johnson (22.21%), Eli Lilly, and Bristol Myers Squibb, and carries a Zacks ETF Rank of 3 (Hold).
Common questions about price, predictions, long-term forecasts, technicals and research methodology.
LLY is currently shown at $1,137.82 in the latest stored market quote. The page is refreshed from the connected market-data pipeline.
US Market AI currently shows quantitative forecasts for 24H, 7D, 30D and 90D using the stored market signals. The forecasts are estimates and not guarantees.
The 2026 long-term forecast section is included as a research framework. A numerical 2026 target is shown only after a dedicated long-horizon model has produced and validated it; the current 24H–90D model is not presented as a 2026 target.
The 2030 section tracks the inputs that a validated long-horizon model should use, including company growth, valuation, earnings, market regime and sector conditions. No unsupported price target is displayed.
The 2035, 2040 and 2050 sections are reserved for long-term model outputs. US Market AI does not invent numerical targets when validated long-horizon data is unavailable.
The page can display RSI, MACD, SMA 50, SMA 200, EMA 20, ATR, ADX, volatility, Bollinger levels, stochastic, support and resistance from stored daily price history.
Fundamental data is not currently populated for this stock, so the page does not estimate or fabricate missing values.
The latest ticker-linked news appears in the Market News section of this page. Stories are shown with source, publication date and sentiment when available.
Only predictions that have matured are evaluated. Recent evaluated outcomes are shown in the model-validation section; accuracy should be interpreted using the full mature sample rather than a single result.
No. US Market AI provides research and model estimates for informational purposes. Forecasts can be wrong and should not be treated as personalized financial advice.
Explore other active stocks in the same sector.
US Market AI combines quantitative signals and verified market data to support research. Forecasts are estimates, can be wrong, and are not financial advice.